Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00372970 · ClinicalTrials.gov registry record · NA
Placebo Controlled Trial of Botulinum Toxin for Gastroparesis
A NA study, sponsored by Temple University.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT00372970 is a NA study that has completed, run by Temple University. The registered enrollment target is 32 participants.
The verdict
NCT00372970, a NA study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
It is hypothesized that in some patients with gastroparesis increased pyloric tone may be a contributing feature. Botox relaxes the pylorus so that food can empty the stomach more rapidly. Lesser quality studies have shown that this treatment works in about 40% of patients, and relieves symptoms for up to 3 months. This study compares this treatment to placebo (saline) injection. After a 1 month period patients may elect to receive open label botox who have not received relief from their first injection. Patients symptoms and gastric emptying are followed for 1 year.
Interventions
- DRUG Placebo
- DRUG Botulinum toxin A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2003-07 |
| Est. Completion | 2008-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00372970
The ClinicalTrials.gov registry entry for NCT00372970 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00372970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00372970 about?
NCT00372970 is a clinical study titled "Placebo Controlled Trial of Botulinum Toxin for Gastroparesis". It is hypothesized that in some patients with gastroparesis increased pyloric tone may be a contributing feature. Botox relaxes the pylorus so that food can empty the stomach more rapidly. Lesser quality studies have shown that this treatment works in about 40% of patients, and relieves symptoms for...
What is the current status of trial NCT00372970?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2003-07. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00372970?
The interventions under investigation include: Placebo (DRUG), Botulinum toxin A (DRUG).
Who is sponsoring clinical trial NCT00372970?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.